Gene Therapy for Relapsed and Refractory Multiple Myeloma is under clinical development by Guangzhou Bio-gene Technology and currently in Phase I for Relapsed Acute Myeloid Leukemia. According to GlobalData, Phase I drugs for Relapsed Acute Myeloid Leukemia have a 71% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Gene Therapy for Relapsed and Refractory Multiple Myeloma’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Gene Therapy for Relapsed and Refractory Multiple Myeloma overview

Gene therapy is under development for the treatment of relapsed and refractory acute myeloid leukemia. The therapeutic candidate comprises of T-cells genetically modified to express chimeric antigen receptor (CAR). It acts by targeting CD33, CD123 and CLL1 surface antigens. It is administered through parenteral route.

For a complete picture of Gene Therapy for Relapsed and Refractory Multiple Myeloma’s drug-specific PTSR and LoA scores, buy the report here.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.